Key Stats for BioCryst Pharmaceuticals Stock
- Price Change: +11.0%
- Current Price: $7.90
- Street Target Price: $21.20
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
BioCryst Pharmaceuticals (BCRX) is gaining massive momentum, with shares rallying 11.0% following a breakout fourth-quarter earnings release that highlighted structural dominance in the rare disease sector.
The biotechnology company delivered full-year ORLADEYO revenue of $601.8 million, representing a staggering 38% increase year over year.
Furthermore, management highlighted its aggressive expansion in the hereditary angioedema (HAE) market, bolstered by the recent acquisition of Astria Therapeutics and the FDA approval of ORLADEYO pellets for young children.
CEO Charlie Gayer detailed exactly why the company’s multi-product strategy creates a highly durable revenue moat.
Gayer stated verbatim: “We view HAE not as a winner-take-all efficacy race, but as a structurally segmented market, driven by biology, patient preference, and real-world experience.”
BioCryst is also rapidly advancing Navenibart, a highly potent injectable treatment that reduces attack rates by up to 92% with dosing required just two to four times a year.
Additionally, the company fortified its balance sheet by entering into a $400 million financing facility with Blackstone Life Sciences to aggressively fund future capital allocation.
See analysts’ growth forecasts and price targets for BioCryst Pharmaceuticals stock (It’s free!) >>>
Is BioCryst Pharmaceuticals Undervalued Today?
Aggregated analyst data indicate that Wall Street is severely underestimating the compounding financial value of BioCryst’s emerging portfolio and scaling profitability.
The consensus Street target price of $21.20 represents a massive 168.4% potential total return from the $7.90 baseline.
Additionally, CFO Babar Ghias explained exactly how the company’s scalable commercial infrastructure is translating top-line growth into record profits.
Ghias stated verbatim: “Our non-GAAP operating profit jumped to $214 million, an increase of 198% year-on-year, the highest ever in BioCryst’s history.”
Read the full BioCryst Pharmaceuticals Transcript on TIKR to see the 2026 guidance breakdown >>>
Valuation Deep Dive
The TIKR Analyst Breakdown identifies BioCryst Pharmaceuticals as a high-margin biotech leader successfully transitioning into a multi-asset commercial powerhouse.
- Street Target Price: $21.20
- Current Price: $7.90
- Implied Upside: 168.4%
The HAE Market Monopoly Strategy: BioCryst is aggressively positioning itself to own the entire prophylactic treatment decision framework for HAE patients. By offering daily oral capsules for adults, oral pellets for children, and the long-acting Navenibart injectable for severe cases, the company ensures patients stay within the BioCryst ecosystem regardless of their preference.
Explosive Scale and Profitability: The commercial engine is operating at peak efficiency. Management highlighted that for every dollar invested in sales and marketing, the company generated an approximate 4x return on ORLADEYO’s net sales. With the European divestiture eliminating loss-making operations, BioCryst is structurally designed to generate immense free cash flow while advancing rare disease pipeline assets like BCX17725.
Conclusion: A revitalized biotech giant successfully leveraging targeted acquisitions and blockbuster oral therapies to accelerate profitability. BioCryst Pharmaceuticals offers an attractive 168.4% projected upside potential. The path to the $21.20 target is paved by record ORLADEYO growth, the Navenibart clinical success, and the $400 million Blackstone partnership.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in BioCryst Pharmaceuticals?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up BioCryst Pharmaceuticals, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track BioCryst Pharmaceuticals alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
[Analyze BioCryst Pharmaceuticals on TIKR Free →]
Looking for New Opportunities?
- See what stock billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
